AbbVie Reaches Agreement for Ovarian Cancer Drug in Canada
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ELAHERE® in Canada. The drug, mirvetuximab soravtansine, is intended for the treatment of platinum-resistant ovarian cancer. This agreement represents an important step toward public reimbursement of the treatment in Canada.
From cantechletter.com
Why it matters
The agreement provides a targeted treatment option for individuals living with FRα-positive, platinum-resistant ovarian cancer. Since ovarian cancer is the leading cause of death from gynecological cancers in Canada, this milestone affects drug market access for a difficult-to-treat disease.
From cantechletter.com
Who's involved
- AbbViePharmaceutical company that reached the drug agreement for ELAHERE® in Canada.
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
Related events
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
- AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- AbbVie and Eli Lilly are competing in the pharmaceutical market.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.